Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nasalfent versus immediate-release morphine for breakthrough cancer pain
2006-003493-97Phase 3Completed
- Sponsor
- Archimedes Development Ltd.
- Start
- Feb 2007
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of fentanyl and morphine in breakthrough cancer pain (BTcP) and cancer pain (2 arms), sponsored by Archimedes Development Ltd. Primary endpoint: Pain Intensity Difference at 15 minutes. Started Feb 2007; status: completed.
02
Drugs
fentanylmorphine
03
Conditions
breakthrough cancer pain (BTcP)cancer pain
Beyond the preview
Go deeper on 2006-003493-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-003493-97.